Volume 70, Numéro 1, Janvier-Février 2015
XXXes Rencontres nationales de Pharmacologie et Recherche clinique, pour l’Innovation et l’Évaluation des Technologies de Santé Tables rondes GIENS – 5 au 6 octobre 2014
|Page(s)||103 - 109|
|Section||Recherche et développement / Research and Developpement|
|Publié en ligne||6 mars 2015|
What Strategy Should France Implement for H2020?
1 DRCD, AP-HP, Hôpital Saint
2 GIRCI Ile-de-France, Hôpital Saint Louis, Paris, France
3 F-CRIN, Toulouse, France
4 Laboratoire Sanofi France, Paris, France
5 Inserm Transfert, Paris, France
6 Laboratoire Boehringer Ingelheim, Paris, France
7 AP-HM, Marseille, France
8 ECRIN, Paris, France
9 CHU de Limoges, Limoges, France
10 Laboratoire Glaxosmithkline, Les Ulis, France
11 Pharmacologie Clinique et Pharmacovigilance, AP-HM, Marseille, France
12 CIC CPCET, Hôpital de la Timone, Marseille, France
13 CHU Purpan, Toulouse, France
14 SR Consulting, Paris, France
15 Agence Nationale de la Recherche, Paris, France
16 DBV Technologies, Bagneux, France
17 French Ministry of Higher Education and Research, Paris, France
18 Truffle Capital, Paris, France
19 Hôpital Fernand Widal, Paris, France
Correspondence and offprints: Jean-François Dhainault, Président du
GIRCI “Île-de-France”, Carré historique, Secteur gris, Porte 23, Hôpital
Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
Vincent Diebolt, F-CRIN, Immeuble AROPA, 35 rue Bernard de Ventadour, 31300 Toulouse, France E-mail: firstname.lastname@example.org
Brigitte Pouletty-Lefevre, Laboratoire Sanofi France, 9 boulevard Romain Rolland, 75159 Paris cedex 14, France. E-mail: email@example.com
Accepted: 30 January 2015
The initiation of Horizon 2020—the European Union’s 8th Framework Programme for Research and Innovation, allotted a budget of 79 billion euros—provides an opportunity to review France’s participation in previous Framework Programmes. Indeed, French participation does not match either its scientific importance or its financial investment. While France contributed 16.5 to 17% of the EU’s 7th Framework Programme research budget, its return through the funding of coordinated projects in which French teams are participating stands at around 12.5 to 13%, a shortfall of 600 million euros. Although the situation depends on the type of activity, French participation in clinical research appears to be smaller than that of its neighbours, with fewer responses to European calls for proposals.
While France has many assets, which include the assured funding of clinical research, structured thematic networks and the initiation of major national programmes, it suffers from the dilution of resources due to France’s regional development policy, the lack of multidisciplinarity and the ignorance of both the medical and scientific community and the institutions to which they belong as to how Horizon 2020 actually works.
We propose three types of strategy to encourage proposals for coordinated clinical research projects or projects involving French teams, and to help in the drawing up of applications: Broaden the vision of our children, students and colleagues, helping them to adapt to the globalisation of knowledge throughout their educational and professional lives. Recognise the value of European actions to influence the European landscape and change mentalities. Help and support project initiators by pooling skills within a limited number of expert centres designed to assist them in their funding application.
• Broaden the vision of our children, students and colleagues, helping them to adapt to the globalisation of knowledge throughout their educational and professional lives.
• Recognise the value of European actions to influence the European landscape and change mentalities.
• Help and support project initiators by pooling skills within a limited number of expert centres designed to assist them in their funding application.
Key words: France / Europe / FP (Framework Programme) / R&I (research and innovation) / Horizon 2020 / information / education / incentive / value / pooling
© 2015 Société Française de Pharmacologie et de Thérapeutique